SURVIVAL AFTER PBSC TRANSPLANTATION AND COMPARISON OF ENGRAFTMENT SPEED WITH AUTOLOGOUS AND ALLOGENEIC MARROW TRANSPLANTATION - RESULTS OF A MULTICENTER STUDY

We have analyzed the results of a multicenter study on peripheral blood stem cell transplantation (PBSCT) performed on 55 patients suffering from various neoplastic diseases. After myeloablative therapy, they received a mediam of 6.8x10(8)/kg MNC and 11.4x10(4)/kg CFU-GM harvested by a median of 9 apheresis after mobilization with chemotherapy alone. As of date, 34 of the 55 patients are alive and 28 of them are in continuous complete remission after a followup of 30 months. The probability of survival was related to the disease status at transplant, CR/PR vs. PD (p=0.0001) and the bone marrow involvement, BM-vs. BM+ (P=0.009). Furthermore, a comparative study on speed of engraftment and clinical management was conducted on the 55 PBSCT patients as well as on 41 autoBMT and 52 alloBMT patients. Days to reach WBC>1.0x10(9)/L, PMN>0.5x10(9)/L and PLT>50x10(9)/L was 12/14/33 for PBSGT, 17/20/23 for ABMT and 15/16.5/18 for BMT, respectively. Days with fever >38 degrees C, systemic antibiotic therapy and length of hospitalization was 3/12/36 for PBSCT, 5/18.5/42 for ABMT and 9/25/46 for BMT respectively.